TGFB1 and small cell lung carcinoma: The efficacy and safety of JS-201, a PD-L1/TGF-β bispecific antibody, combined with lenvatinib in the treatment of SCLC that has failed previous chemotherapy combined with anti-PD-L1 are under investigation in a phase II trial (NCT04951947).